Critical Therapeutics Inc (fka CRTX)

[infitvest]

Up­dat­ed: Cor­texyme's un­ortho­dox Alzheimer's ap­proach tripped up by FDA hold
Up­dat­ed: Cor­texyme's un­ortho­dox Alzheimer's ap­proach tripped up by FDA hold


QUESTIONS INVESTORS SHOULD BE ASKING THEMSELVES:
WHAT HAPPENS ON EITHER THE "EFFECTIVE" 40MG or 80MG DOSE per FDA?** Maybe someone will argue it doesn't happen with the 40mg dose? I argue that's not the most effective dose and also argue that its only a matter of time till the same issues with the liver happen**

*In February 2021 (Only 3 months ago), the FDA placed a partial clinical hold on GAIN because of liver abnormalities in some participants (press release). Dosing in the open-label extension was stopped. Cortex characterized the liver effects as reversible and showing no risk of long-term effects. (How were they reversible? by discontinuing the medicine? How does that help LONG TERM TREATMENT?*

****If I was a new CRTX investor****, the 15 minutes of researching would pull up a bunch of older articles making claims (like those have NEVER been done before). Followed by articles highlighting the CEO selling massive amounts of shares, Followed my investigational lawsuits, Followed by the FDA HAULTING their extension due safety, Followed by a really bad performance by the CEO in April (pipeline question = bad, fda explanation = bad, looking visibly upset cause you have to answer why your drug isn't safe long term = bad.... )The individual questioning her was incredibly smart to pretty much let investors know that CRTX has a extremely limited chance at AD approval.

From Yahoo Finance:
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX

New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at [e-mail] or 888-476-6529, ext. 7980.

The investigation concerns whether Cortexyme and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.


On February 15, 2021, Cortexyme announced receipt of "a letter from the U.S. Food and Drug Administration (FDA) stating that a partial clinical hold has been placed on atuzaginstat (COR388) impacting the open-label extension (OLE) phase of the company's ongoing Phase 2/3 study, the GAIN Trial." Cortexyme advised that, as a result of the partial clinical hold, "no new participants will be enrolled in the OLE and currently enrolled OLE participants will be discontinued." According to the Company, "the partial clinical hold was initiated following the review of hepatic adverse events in the atuzaginstat trial by the FDA."

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[e-mail]
888-476-6529 ext. 7980